> top > docs > PubMed:33225970 > annotations

PubMed:33225970 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
2 100-108 Disease denotes COVID-19 MESH:C000657245
3 118-126 Species denotes patients Tax:9606
38 340-348 Species denotes patients Tax:9606
39 354-362 Disease denotes COVID-19 MESH:C000657245
40 363-372 Disease denotes infection MESH:D007239
41 528-536 Species denotes patients Tax:9606
42 792-804 Species denotes PARTICIPANTS Tax:9606
43 806-814 Species denotes Patients Tax:9606
44 829-834 Disease denotes COVID MESH:C000657245
45 977-985 Species denotes Patients Tax:9606
46 1001-1009 Disease denotes COVID-19 MESH:C000657245
47 1335-1340 Chemical denotes water MESH:D014867
48 1371-1390 Species denotes Zingiber officinale Tax:94328
49 1392-1398 Species denotes Ginger Tax:94328
50 1410-1423 Species denotes Embelia ribes Tax:459629
51 1439-1457 Species denotes Glycyrrhiza glabra Tax:49827
52 1470-1488 Species denotes Terminalia chebula Tax:155022
53 1500-1520 Species denotes Tinospora cordifolia Tax:285590
54 1534-1553 Species denotes Asparagus racemosus Tax:272846
55 1566-1585 Species denotes Emblica officinalis Tax:296036
56 1597-1609 Species denotes Piper longum Tax:49511
57 1666-1672 Chemical denotes starch MESH:D013213
58 1747-1755 Species denotes Patients Tax:9606
59 1794-1798 Gene denotes IP-1 Gene:8517
60 1803-1807 Gene denotes IP-2 Gene:8517
61 1872-1876 Gene denotes IP-2 Gene:8517
62 1953-1958 Chemical denotes water MESH:D014867
63 2387-2395 Species denotes patients Tax:9606
64 2538-2541 Gene denotes TH1 Gene:51497
65 2554-2557 Gene denotes IL6 Gene:3569
66 2972-2984 Species denotes Participants Tax:9606
67 3070-3082 Species denotes Participants Tax:9606
68 3204-3212 Species denotes patients Tax:9606
69 3539-3546 Species denotes patient Tax:9606
70 3588-3595 Species denotes patient Tax:9606
71 3783-3794 Species denotes Participant Tax:9606

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T1 2831-2835 Phenotype denotes rash http://purl.obolibrary.org/obo/HP_0000988
T2 2837-2844 Phenotype denotes itching http://purl.obolibrary.org/obo/HP_0000989
T3 2862-2871 Phenotype denotes dizziness http://purl.obolibrary.org/obo/HP_0002321
T4 2873-2890 Phenotype denotes trouble breathing http://purl.obolibrary.org/obo/HP_0002094

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T1 0-158 Sentence denotes Safety and efficacy of herbal extracts to restore respiratory health and improve innate immunity in COVID-19 positive patients with mild to moderate severity:
T2 159-234 Sentence denotes A structured summary of a study protocol for a randomised controlled trial.
T3 235-246 Sentence denotes OBJECTIVES:
T4 247-373 Sentence denotes Primary Objective • To assess the efficacy of herbal extracts in boosting innate immunity of patients with COVID-19 infection.
T5 374-503 Sentence denotes Secondary Objectives • To assess the efficacy of herbal extracts in restoring respiratory health • To assess the efficacy of Cap.
T6 504-618 Sentence denotes IP in early recovery of patients and decline in viral load • To assess the safety of herbal extracts TRIAL DESIGN:
T7 619-791 Sentence denotes This is a single centre, randomized, 2-arm, parallel group, double blind, 1:1 ratio, controlled, exploratory trial with a study period of 30 days from the day of enrolment.
T8 792-805 Sentence denotes PARTICIPANTS:
T9 806-976 Sentence denotes Patients attending the COVID treatment centre at Yashwantrao Chavan Memorial Hospital, Nehrunagar, Pimpri, Pune, India were screened for their participation in the study.
T10 977-1091 Sentence denotes Patients who were known COVID-19 positive (with positive RT-PCR), eligible and willing were enrolled in the study.
T11 1092-1120 Sentence denotes INTERVENTION AND COMPARATOR:
T12 1121-1181 Sentence denotes The intervention in the trial has a background in 'Ayurved'.
T13 1182-1199 Sentence denotes Intervention Arm:
T14 1200-1645 Sentence denotes Two capsules, Investigational Product (IP) - 1 - 400mg and Investigational Product - 2 - 450mg, containing herbal extracts (a blend of water and CO2 extracts) of Shunthi (Zingiber officinale (Ginger), Vidanga (Embelia ribes), Yashtimadhu (Glycyrrhiza glabra), Haritaki (Terminalia chebula), Guduchi (Tinospora cordifolia), Shatavari (Asparagus racemosus), Aamalaki (Emblica officinalis), Pippali (Piper longum) and calcined Zinc, Shankha bhasma.
T15 1646-1658 Sentence denotes Placebo Arm:
T16 1659-1682 Sentence denotes Edible starch ~ 450 mg.
T17 1683-1746 Sentence denotes The look and feel of IP and of Placebo boxes were very similar.
T18 1747-1902 Sentence denotes Patients are to take two capsules (one each of IP-1 and IP-2) twice a day for 15 days, and from the 16th day, one capsule of IP-2 twice a day up-to day 30.
T19 1903-1959 Sentence denotes Capsules are to be administered orally with plain water.
T20 1960-2063 Sentence denotes The IP is to be taken with all other concomitant medicines prescribed by the treating physician/doctor.
T21 2064-2128 Sentence denotes The dose of each component in the IP is very safe to administer.
T22 2129-2301 Sentence denotes The investigational products are registered products with the Indian Government and have been used for more than 6 months in various health conditions but not for COVID-19.
T23 2302-2316 Sentence denotes MAIN OUTCOMES:
T24 2317-2333 Sentence denotes Primary Outcome:
T25 2334-2433 Sentence denotes Efficacy of the herbal extracts in COVID 19 positive patients (in declining viral load: time-point:
T26 2434-2480 Sentence denotes 4 days and early recovery) Secondary Outcomes:
T27 2481-2652 Sentence denotes Efficacy of the herbal extracts as an immune-modulator - TH1, TH2, Th17, IL6, NK Cells and CD markers; Immunoglobulin IGG (Serum); Immunoglobulin IGM (Serum) - at 30 days.
T28 2653-2891 Sentence denotes Efficacy of the investigational product in reducing sequela of the disease Safety analysis (Liver Function Test and Kidney Function Test) including serious allergic reaction of: rash, itching/swelling, severe dizziness, trouble breathing.
T29 2892-2906 Sentence denotes RANDOMISATION:
T30 2907-2971 Sentence denotes An alphanumeric coded set of IP/Placebo containers will be used.
T31 2972-3049 Sentence denotes Participants will be automatically randomized to two groups in the ratio 1:1.
T32 3050-3069 Sentence denotes BLINDING (MASKING):
T33 3070-3126 Sentence denotes Participants, caregivers and investigators were blinded.
T34 3127-3166 Sentence denotes NUMBERS TO BE RANDOMISED (SAMPLE SIZE):
T35 3167-3289 Sentence denotes A total of more than 60 and up to 75 patients were to be enrolled in the study into the two groups, considering drop-outs.
T36 3290-3373 Sentence denotes 72 were enrolled with 37 into the intervention group and 35 into the placebo group.
T37 3374-3387 Sentence denotes TRIAL STATUS:
T38 3388-3404 Sentence denotes Protocol number:
T39 3405-3442 Sentence denotes CoviQuest-01 Protocol version number:
T40 3443-3461 Sentence denotes 1.2 Protocol Date:
T41 3462-3526 Sentence denotes 1st July 2020 The recruitment period is completed for the trial.
T42 3527-3634 Sentence denotes Date of 1st patient enrolment was 11th Aug 2020 and the last patient was enrolled on 3rd of September 2020.
T43 3635-3777 Sentence denotes This is to state that it was a late submission from authors for publication of the protocol to the BMC, after enrolment in the study was over.
T44 3778-3864 Sentence denotes Last Participant's last follow-up is scheduled on 5th October 2020 TRIAL REGISTRATION:
T45 3865-3953 Sentence denotes The trial was prospectively registered with the CTRI (Clinical Trial Registry of India).
T46 3954-3998 Sentence denotes Registration number is CTRI/2020/07/026570 .
T47 3999-4040 Sentence denotes Registered on 14 July 2020 FULL PROTOCOL:
T48 4041-4149 Sentence denotes The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1).
T49 4150-4330 Sentence denotes In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.

wangzhuo19_800_3

Id Subject Object Predicate Lexical cue
T1 23-38 CI denotes herbal extracts
T18 1646-1653 CI denotes Placebo
T19 1714-1721 CI denotes Placebo
T2 293-308 CI denotes herbal extracts
T20 2939-2946 CI denotes Placebo
T21 3359-3366 CI denotes placebo
T22 2936-2938 CI denotes IP
T23 504-506 CI denotes IP
T24 1239-1241 CI denotes IP
T25 1704-1706 CI denotes IP
T26 1794-1796 CI denotes IP
T27 1803-1805 CI denotes IP
T28 1872-1874 CI denotes IP
T29 1964-1966 CI denotes IP
T3 423-438 CI denotes herbal extracts
T30 2098-2100 CI denotes IP
T31 100-108 DP denotes COVID-19
T32 354-362 DP denotes COVID-19
T33 1001-1009 DP denotes COVID-19
T34 2292-2300 DP denotes COVID-19
T35 2369-2377 DP denotes COVID 19
T4 589-604 CI denotes herbal extracts
T5 1307-1322 CI denotes herbal extracts
T6 2350-2365 CI denotes herbal extracts
T7 2497-2512 CI denotes herbal extracts

maxiaofeng52_800_3

Id Subject Object Predicate Lexical cue
T1 23-38 CI denotes herbal extracts
T10 1001-1009 DP denotes COVID-19
T11 2292-2300 DP denotes COVID-19
T12 1646-1653 CI denotes Placebo
T13 1714-1721 CI denotes Placebo
T14 2939-2946 CI denotes Placebo
T15 1239-1241 CI denotes IP
T16 504-506 CI denotes IP
T17 1704-1706 CI denotes IP
T18 1794-1796 CI denotes IP
T19 1803-1805 CI denotes IP
T2 293-308 CI denotes herbal extracts
T20 1872-1874 CI denotes IP
T21 1964-1966 CI denotes IP
T22 2098-2100 CI denotes IP
T23 2936-2938 CI denotes IP
T24 2369-2377 DP denotes COVID 19
T3 423-438 CI denotes herbal extracts
T4 589-604 CI denotes herbal extracts
T5 1307-1322 CI denotes herbal extracts
T6 2350-2365 CI denotes herbal extracts
T7 2497-2512 CI denotes herbal extracts
T8 100-108 DP denotes COVID-19
T9 354-362 DP denotes COVID-19
T25 3359-3366 CI denotes placebo